Entrepreneur-in-Residence; EIR – Liquid Biopsy Services

The Company

Alloy Therapeutics — a biotechnology ecosystem company empowering the global scientific community to make better medicines together. We democratize access to pre-competitive tools, technologies, services, and company creation capabilities to support discovery and development of therapeutic biologics. We aim to enable affordable, non-exclusive access to the drug discovery community from academic scientists to large biopharma. We reinvest 100% of our revenue in innovation and access to innovation.

Alloy is headquartered in Waltham, MA with additional labs in Cambridge, UK;
Basel, Switzerland; and Athens, GA. We foster a culture of accountability, deliberate trust, and open communication, and seek to exceed expectations while maintaining a nimble, startup culture. This is an on-site and full-time position in Waltham, MA. We uphold an ethos of mentorship and value in-person collaboration where needed to interact organically and face-to-face.

The Office of the CEO (OCEO) at Alloy Therapeutics functions as a strategic thought partner across the executive leadership team. It drives and manages a broad range of corporate priorities to advance the Alloy ecosystem. The OCEO:

• Partners directly with C-suite leaders to facilitate high-priority initiatives
• Coordinates execution across the company, aligning efforts across Business Development, Scientific, Legal, Finance, and Venture Creation
• Delivers tools, processes, and analyses that support strategic decision-making and execution at all levels of the organization – including across Alloy and its affiliated venture studio, 82VS

We are seeking an experienced Entrepreneur-in-Residence (EIR) to lead the development and launch of a clinical testing service focused on circulating tumor DNA (ctDNA) analysis in liquid biopsies. This role will define and implement a differentiated service offering that leverages cutting-edge, ultra-high-sensitivity sequencing technologies to support oncology product development, translational research, and clinical decision-making. The EIR will operate at the intersection of technology, clinical diagnostics, and business strategy, with the mandate to assess market opportunity, establish technical and operational foundations, and build a scalable clinical testing platform aligned with current and future oncology product offerings.

• Develop:
  The strategic vision, value proposition, and business model for a ctDNA-based clinical testing service
• Lead:
  Selection, development, and implementation of high-sensitivity clinical testing assays
• Drive:
  Establishment and scaling of CLIA/CAP-compliant clinical testing laboratories
• Partner:
  With regulatory and payer experts to define reimbursement and commercial strategy
• Collaborate:
  Closely with internal and external stakeholders to ensure clinical testing services are tightly aligned with Alloy Therapeutics’ broader drug development strategy

Service & Business Development

• Define priority indications and clinical contexts where ctDNA provides clear decision-making value (e.g., MRD, therapy monitoring, resistance)
• Determine optimal platform strategy across assay development, sequencing technologies, and bioinformatics (build, partner, or acquire)
• Design commercial models and customer engagement strategies for biopharma, clinical trial, and healthcare delivery settings

Technology & Assay Strategy

• Select and operationalize ultra-sensitive sequencing and error-correction approaches appropriate for each clinical use case
• Establish analytical performance benchmarks and validation frameworks to ensure robust, reproducible results
• Drive assay lifecycle management, including optimization, scalability, and turnaround times suitable for prospective clinical use
• Guide bioinformatics and variant interpretation approaches for ultra-low allele frequency detection

Clinical & Regulatory Enablement

• Implement CLIA/CAP laboratory workflows and quality systems to support clinical testing deployment
• Define regulatory positioning across LDTs, clinical trial support, companion diagnostics, and future IVD pathways
• Partner with reimbursement and health-economics…